The future of cancer research Prevention, screening, vaccines, and tumor-specific drug combos

被引:1
|
作者
Blanck, George [1 ,2 ]
机构
[1] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA
关键词
cancer and diet; cancer and inflammation; cancer prevention; cancer screening; cancer vaccines; carcinogens; designer drugs; tumor promoters; tumor-specific drugs; ACQUIRED-RESISTANCE; SOMATIC MUTATIONS; THERAPY; GENOME;
D O I
10.4161/hv.27458
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
New cancer research strategies have developed very rapidly over the past five years, including extensive DNA sequencing of tumor and normal cells; use of highly sensitive cancer cell detection methods; vaccine development and tumor-specific (designer) drugs. These developments have raised questions about where to concentrate efforts in the near future when establishing clinical trials, particularly important in an age of diminishing resources and during a period when competing strategies for cancer control are likely to overwhelm the opportunities for establishing large, effective clinical trials. In particular, it behooves the research community to be mindful of the inevitable, challenging obligation to responsibly choose between clinical trials that offer the credible hope of incremental advances vs. trials that are less traditional but may have revolutionary outcomes.
引用
收藏
页码:700 / 702
页数:3
相关论文
共 50 条
  • [1] Is prevention of cancer possible with tumor-specific vaccines?
    Demiroglu, H
    MEDICAL HYPOTHESES, 1997, 49 (03) : 281 - 284
  • [2] Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination
    Hailemichael, Yared
    Overwijk, Willem W.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 53 : 46 - 50
  • [3] Protocol Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities
    Calandrini, Camilla
    Drost, Jarno
    STAR PROTOCOLS, 2022, 3 (01):
  • [4] TUMOR-SPECIFIC IMMUNE-RESPONSES AND OPPORTUNITIES FOR TUMOR VACCINES
    FINN, OJ
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 71 (03): : 260 - 262
  • [5] Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
    Zhou, G
    Drake, CG
    Levitsky, HI
    BLOOD, 2006, 107 (02) : 628 - 636
  • [6] Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer
    Zhang, Jian
    Pan, Tony
    Lee, Jimmy
    Goldberg, Sanja
    King, Sarah Ann
    Tang, Erting
    Hu, Yifei
    Chen, Lifeng
    Hoover, Alex
    Zhu, Linyong
    Eng, Oliver S.
    Dekel, Benjamin
    Huang, Jun
    Wu, Xiaoyang
    CELL REPORTS MEDICINE, 2025, 6 (01)
  • [7] Nanoparticles for Tumor-specific Intracellular Drug Delivery
    Yeo, Yoon
    Xu, Peisheng
    2009 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-20, 2009, : 2403 - 2405
  • [8] Clostridium spores for tumor-specific drug delivery
    Nuyts, S
    Van Mellaert, L
    Theys, J
    Landuyt, W
    Lambin, P
    Anné, J
    ANTI-CANCER DRUGS, 2002, 13 (02) : 115 - 125
  • [9] Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines
    Grohmann, U
    Bianchi, R
    Belladonna, ML
    Silla, S
    Surace, D
    Fioretti, MC
    Puccetti, P
    DENDRITIC CELLS IN FUNDAMENTAL AND CLINICAL IMMUNOLOGY, VOL 3, 1997, 417 : 579 - 582
  • [10] Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity
    Ressing, ME
    Offringa, R
    Toes, REM
    Ossendorp, F
    deJong, JH
    Brandt, RMP
    Kast, WM
    Melief, CJM
    IMMUNOTECHNOLOGY, 1996, 2 (04): : 241 - 251